Insulin Initiation in Type 2 Diabetes – Why, When and How?

Open access

Abstract

Type 2 diabetes is a progressive disease and, despite recent progress in the treatment of diabetes, the glycemic control usually deteriorates gradually and insulin therapy is needed. When insulin therapy should be started and which are the appropriate insulin therapy strategies, still represent subjects of debates. Insulin represents a therapeutic option in type 2 diabetes due to the existence of early β-cell dysfunction and significant reduction of β-cell mass in natural history of type 2 diabetes. The current guidelines recommend insulin in double therapy in association with metformin or in combination with metformin and other noninsulin agent. Initiation of insulin therapy is recommended in patients with newly diagnosed type 2 diabetes and symptomatic and/or presenting important hyperglycemia or elevated HbA1c. Initiation of insulin therapy in type 2 diabetes should take into consideration the pathophysiology of type 2 diabetes, the effects and the potential risks of insulin therapy, the guidelines recommendations and the barriers to insulin use. Literatures of only English language were analyzed from NCBI database. Guidelines were accessed electronically from organisations, i.e. American Diabetes Associations, American Association of Clinical Endocrinologists and American College of Endocrinology, European Association for the Study of Diabetes, International Diabetes Federation.

1. Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55: 1114-1120, 2006.

2. Funakoshi S, Fujimoto S, Hamasaki A et al. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 82: 353-358, 2008.

3. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291: 335-342, 2004.

4. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467): 1333-1346, 2005.

5. UKPDS Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44: 1249-1258, 1995.

6. Riccardo C. Patogenesi dell’iperglicemia nel diabete di tipo 2. In: Bolli G, Del Prato S, Riccardi G., editors. La terapia insulinica. Primula pp 64-82, 2007.

7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.

8. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47: 943-956, 2004.

9. Deng S, Vatamaniuk M, Huang X et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53: 624-632, 2004.

10. Poitout V, Robertson RP. Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143: 339-342, 2002.

11. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. Postgrad Med 109: 55-59, 63-64, 2001.

12. Marchetti P, Bugliani M, Lupi L et al. The pancreatic beta-cell in human type 2 diabetes. In: Marchetti P, Matthews D (Eds). Pancreatic beta-cell in human type 2 diabetes. Wiley-Blackwell, pp 49-63, 2009.

13. Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89: 5535-5541, 2004.

14. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193–203, 2009.

15. DeFronzo RA. Obiettivi del trattamento del diabete. In: DeFronzo RA editor. Terapia attuale del diabete melito. Mosby Italia. pp 5-7, 1999.

16. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23: B21-B29, 2000.

17. Abraira C, Colwell J, Nuttall F et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes. Arch Intern Med 157: 181-188, 1997.

18. Sourij H, Schmoelzer I, de Campo A et al. Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes. Eur J Endocrinol 165: 269-274, 2011.

19. Miller ME, Bonds DE, Gerstein HC et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340:b5444, 2010.

20. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev (2):CD005613, 2007.

21. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 18[Suppl. 3]: S42–S49, 2002.

22. Shah PK, Mudaliar S, Chang AR et al. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 13: 505-510, 2011.

23. Andrews WJ, Vasquez B, Nagulesparan M et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33: 634-642, 1984.

24. Belfiore A, Malaguarnera R. The insulin receptor and cancer. Endocr Relat Cancer 18: R125-R147, 2011.

25. Corpet DE, Jacquinet C, Peiffer G, Taché S. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr Cancer 27: 316-320, 1997.

26. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 150: 1071-1087, 1997.

27. Gamble JM, Simpson SH, Eurich D, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 12: 47-53, 2010.

28. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 7: 625-631, 2000.

29. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003.

30. Del Prato S, Felton AM, Munro N et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 59: 1345-1355, 2005.

31. Bianchi C, Del Prato S. La terapia insulinica nel diabete mellito di tipo 2. In: Bolli G, Del Prato S, Riccardi G., editors. La terapia insulinica. Primula pp. 28-39, 2007.

32. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371(9626): 1753-1760, 2008.

33. Alvarsson M, Sundkvist G, Lager I et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26: 2231-2237, 2003.

34. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27: 1028-1032, 2004.

35. Saisho Y, Kou K, Tanaka K et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 58: 315-322, 2011.

36. Goto A, Takaichi M, Kishimoto M et al. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 57: 237-244, 2010.

37. Garber AJ, Abrahamson MJ, Barzilay JI et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract 22: 84-113.

38. American Diabetes Association. Standards of Medical Care in Diabetes 2016. Diabetes Care 39[Suppl. 1]: S52–S59, 2016

39. Canadian Diabetes Association. 2008 Clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 32[Suppl. 1]: S53-S62, 2008.

40. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005. Available at: https://www.idf.org/global-guideline-type-2-diabetes-2005

41. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA 289: 2265-2269, 2003.

42. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289: 2254-2264, 2003.

43. Goudswaard AN, Stolk RP, Zuithoff P, De Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 53: 393-399, 2004.

44. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28: 260-265, 2005.

45. Buse JB, Wolffenbuttel BH, Herman WH et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 32: 1007-1013, 2009.

46. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 22: 453–458, 2007.

47. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 28: 600-606, 2005.

48. Hamaty M. Insulin treatment for type 2 diabetes: When to start, which to use. Cleve Clin J Med 78: 332-342, 2011.

49. Plonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin 27: 1169-1174, 2011.

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

The Journal of Romanian Society of Diabetes Nutrition and Metabolic Diseases

Journal Information


CiteScore 2017: 0.11

SCImago Journal Rank (SJR) 2017: 0.122
Source Normalized Impact per Paper (SNIP) 2017: 0.077

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 289 282 16
PDF Downloads 133 132 8